Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

BACKGROUND: The benefit of adjuvant chemotherapy (ACT) in pathological T2N0M0 non-small-cell lung cancer (NSCLC) patients is not clear. METHODS: One thousand and fifty pathological T2N0M0 NSCLC patients were included and divided into two groups: with and without ACT. A propensity score matching anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, X., Yang, M.-Z., Li, J.-B., Tan, Z.-H., Long, H., Fu, J.-H., Zhang, L.-J., Lin, P., Yang, H.-X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184557/
https://www.ncbi.nlm.nih.gov/pubmed/35688064
http://dx.doi.org/10.1016/j.esmoop.2022.100508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184557/
https://www.ncbi.nlm.nih.gov/pubmed/35688064
http://dx.doi.org/10.1016/j.esmoop.2022.100508

Ejemplares similares